Outcomes before and after treatment escalation to Global Initiative for @entity565 and 5 in severe XXXX .

@entity1 @entity283 @entity565 @entity229 @entity228 @entity1613 @entity5023
BACKGROUND: Little is known about health outcomes in severe @entity565 reflected by Global Initiative for @entity565 and  5. OBJECTIVE: To analyze control, risk, economic, and @entity283 ( @entity283 ) outcomes associated with treatment escalation to Global Initiative for @entity565 and  5. METHODS: This was a before-vs-after retrospective cohort study of @entity1 (12-75 years old) with @entity565 newly @entity1613 , high-intensity corticosteroids (HICS; >= 1,000  g/day of inhaled @entity5023 equivalent or oral @entity229 ), or high-dose inhaled corticosteroid (HDICS; >= 500 to <1,000  g/day of @entity5023 equivalent) using 2002 to 2011 MarketScan data. Poisson regression was used to model @entity283 outcomes; Tobit regression was used to model medical expenditures. RESULTS: Of 19,227 @entity1 , 856 @entity1613 , 6,926 initiated HICS, and 11,445 initiated HDICS. Use of b-agonist increased for the HDICS and HICS cohorts and decreased for the omalizumab cohort; acute care visits and oral @entity228 use decreased during follow-up for the HDICS and omalizumab cohorts. Annual health care expenditures, polypharmacy burden, and outpatient visits were high for all cohorts and increased in the follow-up year (baseline to follow-up; general health care expenditures: omalizumab  14,071 to  34,887, HICS  12,030 to  15,557, HDICS  7,570 to  9,826; annual number of @entity565 prescriptions: omalizumab 11.74 to 19.46, HICS 7.8 to 12.44, HDICS 5.17 to 9.69; outpatient visits: omalizumab 26.79 to 34.06, HICS 18.78 to 21.37, HDICS 15.06 to 16.64). CONCLUSION: Omalizumab use was associated with improvements in risk and control accompanied by large increases in expenditures per @entity283 . @entity1 on HDICS and HICS showed improvements in risk but worsening control and increased expenditures per @entity283 . Innovations in disease management and available treatment options are needed to more optimally achieve treatment goals.
